ILYM17121 / Verastem / Carla CasuloResearch Question:
What is the effect of oral medicine, duvelisib, in patients with relapsed or refractory
Peripheral T cell Lymphoma (PTCL)?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an
oral dual inhibitor of PI3K-δ,γ, in patients with relapsed or refractory Peripheral
T cell Lymphoma (PTCL).
Study Reference #: ILYM-17121
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Amber Johnson
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search